IRIDEX Corporation (NASDAQ:IRIX) Q1 2021 Earnings Conference Call May 11, 2021 5:00 PM ET Company Participants Hunter Cabi - Investor Relations Dave Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Scott Henry - ROTH Capital Operator Good day and thank you for standing by. Welcome to the Q1 2021 IRIDEX Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakersÂ' presentation, there will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITY EXCHANGE ACT OF 1934 For the fiscal year ended January 2, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITY EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-27598 IRIDEX CORPORATION (Exact name of Registrant as specified in its charter) | Delaware 77-0210467 | | --- | | (State or other jurisdicti ...

Iridex Corporation (NASDAQ:IRIX) Q4 2020 Results Conference Call March 22, 2021 5:00 PM ET Company Participants Leigh Salvo - IR David Bruce - CEO Fuad Ahmad - Interim CFO Conference Call Participants Jonathan Block - Stifel Operator Ladies and gentlemen, thank you for standing by, and welcome to the Iridex Q4 and Full Year 2020 Conference Call. At this time, all participants are in listen-only mode. After the speakersÂ' presentation, there will be a question-and-answer session. [Operator Instructions]. As ...

IRIDEX Corporation (NASDAQ:IRIX) Q3 2020 Earnings Conference Call November 9, 2020 5:00 PM ET Company Participants Hunter Cabi – Investor Relations Dave Bruce – Chief Executive Officer Jim MacKaness – Interim Chief Financial Officer Conference Call Participants Thomas Stephan – Stifel Scott Henry – ROTH Capital Paul Nouri – Noble Equity Operator Ladies and gentlemen, thank you for standing by, and welcome to the IRIDEX Third Quarter 2020 Earnings Conference Call. At this time, all participants are in a list ...

IRIDEX Corporation (NASDAQ:IRIX) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Hunter Cabi – Investor Relations Dave Bruce – Chief Executive Officer Jim MacKaness – Interim Chief Financial Officer Conference Call Participants Tom Stephan – Stifel Scott Henry – ROTH Capital Operator Ladies and gentlemen, thank you for standing by, and welcome to the Second Quarter 2020 IRIDEX Earnings Conference Call. At this time, all participant lines are in a listen-only mode. After the s ...

IRIDEX Corporation (NASDAQ:IRIX) Q1 2020 Earnings Conference Call May 11, 2020 5:00 PM ET Company Participants Leigh Salvo - Investor Relations David Bruce - Chief Executive Officer Jim MacKaness - Interim Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Scott Henry - Roth Capital Operator Ladies and gentlemen, thank you for standing by and welcome to the First Quarter 2020 IRIDEX Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker p ...

Financial Performance - Total revenues increased by $0.8 million or 2.0% from $42.6 million in 2018 to $43.4 million in 2019, primarily due to a 10.6% increase in G6 product sales[200] - Gross profit rose by $0.5 million or 2.7% from $17.5 million in 2018 to $17.9 million in 2019, with gross margin improving from 41.0% to 41.3%[202] - Net loss narrowed to $8.8 million in 2019 from $12.8 million in 2018, with a loss from operations improving from (30.2%) to (20.7%) of revenues[192][199] Expenses - Research and development expenses decreased by $0.3 million or 8.1% from $4.0 million in 2018 to $3.7 million in 2019[204] - Sales and marketing expenses fell by $1.9 million or 11.5%, from $16.8 million in 2018 to $14.9 million in 2019[205] - General and administrative expenses decreased by $1.2 million or 12.3% from $9.6 million in 2018 to $8.4 million in 2019[206] Cash Flow and Liquidity - Cash and cash equivalents decreased to $12.7 million as of December 28, 2019, down from $21.2 million at the end of 2018[210] - Net cash used in operating activities improved to $7.9 million in 2019 from $10.0 million in 2018, driven by higher cash collections and reduced operating expenses[211] - The company believes existing cash and cash equivalents and available credit will be sufficient to meet anticipated cash needs over the next 12 months[214] Tax and Valuation - The company recorded a provision for income taxes of $48 thousand in 2019, compared to $37 thousand in 2018, with an effective tax rate of negative 0.46%[208] - As of December 28, 2019, a full valuation allowance was provided on federal and state deferred tax assets due to recent history of losses[224] Inventory and Reserves - Inventories are stated at the lower of cost or net realizable value, with adjustments made for estimated excess, obsolete, or impaired inventory[220] - The company maintains allowances for doubtful accounts based on past payment history, current financial condition, and aging of accounts receivable[222] - Warranty reserves are provided based on historical product failure rates and expected costs, with a general two-year warranty on products[223] Accounting Standards and Disclosures - The company adopted ASU 2016-02 on December 30, 2018, resulting in an increase in assets of $4.0 million and liabilities of $4.5 million due to operating lease obligations[231] - The company early adopted ASU 2018-13 in fiscal year 2019, which did not have a material impact on consolidated financial statements[232] - The company does not have any off-balance sheet arrangements[235] - As a smaller reporting company, the company is not required to provide certain market risk disclosures[236]

IRIDEX Corp (NASDAQ:IRIX) Q4 2019 Earnings Conference Call March 12, 2020 5:00 PM ET Company Participants Leigh Salvo - Head, IR David Bruce - President, CEO & Director Romeo Dizon - VP, Finance & Controller Conference Call Participants Jonathan Block - Stifel, Nicolaus & Company Scott Henry - Roth Capital Partners Operator Ladies and gentlemen, thank you for standing by, and welcome to the IRIDEX Fourth Quarter 2019 Earnings Call. [Operator Instructions]. I would now like to hand the conference over to you ...

Glaucoma Market and Solution - The global glaucoma market is a $5 billion market [7] - IRIDEX offers MicroPulse Transscleral Laser Therapy as a non-incisional solution for glaucoma, targeting ciliary body tissue to reduce IOP [11] - Clinical outcomes show a 39% IOP reduction at a mean of 78 months follow-up [8, 14] - Over 120,000 MicroPulse procedures have been performed globally since 2015 [16] Market Opportunity and Penetration - The U S probe opportunity is estimated at $500 million [12] - The Rest of World (ROW) probe opportunity is estimated at $700 million [13] - IRIDEX's U S 2019 MP3 probe run rate is 25,000 [12] - IRIDEX's ROW 2019 MP3 volume run rate is 25,000 [13] Financials and Growth - 2019 Revenue Guidance is $41 million to $44 million [27] - As of September 28, 2019, IRIDEX had $12 9 million in cash and no debt [27]

IRIDEX Corporation (NASDAQ:IRIX) Q3 2019 Earnings Conference Call November 7, 2019 5:00 PM ET Company Participants Leigh Salvo – Head of Investors Relations Dave Bruce – Chief Executive Officer Romeo Dizon – Vice President of Finance Conference Call Participants Scott Henry – Roth Capital Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q3 2019 IRIDEX Earnings Conference Call. [Operator Instructions] Please be advised that todayÂ's conference is being recorded. [Operator Instruct ...